Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Agnese Losurdo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

A. Losurdo1, R. De Sanctis1, B. Fernandes2, V. Errico3, A. Sagona3, G. Masci1, M. Zuradelli1, E. Agostinetto1, R. Torrisi1, W. Gatzemeier3, A. Testori3, M. Roncalli2, M. Alloisio3, C. Tinterri3, A. Santoro1

Author affiliations

  • 1 Medical Oncology And Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 2 Pathology, Humanitas Cancer Center, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 3 Breast Surgery, Humanitas Cancer Center, Istituto Clinico Humanitas, 20089 - Rozzano (Milan)/IT
More

Resources

Abstract 4448

Background

TILs have been proposed as a prognostic biomarker in many tumor types both in the adjuvant and neoadjuvant setting. In TNBC, TILs are present at the highest level and have been demonstrated to be associated with better prognosis. TNBC is a highly diverse group of cancers and subtyping is necessary to better identify patient-tailored therapies. Cluster analysis by gene expression identified 6 TNBC subtypes among which the so called “luminal androgen receptor subtype”.

Methods

We retrospectively collected 160 early stage TNBC consecutively treated at our Institution from 2006 to 2015. Data were obtained for clinico-pathological patients' characteristics. On IHC archive slides we analyzed stromal TILs scored as a continuous variable and androgen receptor's (AR) percentage and intensity of expression. We performed Cox analyses for DFS and for OS, and we used chi-square and Fisher test to evaluate the correlation between TILs, AR and other clinical variables. To define high vs low TILs, an internal dataset cut-off of 10% was considered.

Results

150 patients were eligible for IHC analyses of TILs and AR. With a median follow-up of 6.5 years, 41 local and/or distant relapse events were observed and 28 patients died of disease. Interestingly, TILs were found to be significantly associated with nodal status (N0 vs N1-3), grading (G2 vs G3) and Ki-67 (<20% vs ≥ 20%) (p = 0.007, p = 0.055 and p = 0.002, respectively). AR was also significantly associated with proliferation, specifically AR-positive cases presented mostly with a Ki-67<20% (p = 0.008). Probably due to the paucity of events, no statistically significant association of TILs and AR with either DFS or OS was observed.

Conclusions

TILs are a promising prognostic marker, but still prospective validation is needed to integrate them into clinical practice. Among TNBC, the identification of AR-expressing luminal subtype might provide a targeted therapy chance for a low proliferation TNBC subtype. Larger prospective trials are likely to validate TILs prognostic role and to explore the universe of TNBC subtypes targeted therapies opportunities.

Clinical trial identification

Legal entity responsible for the study

Istituto Clinico Humanitas.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings